Histone deacetylases and epigenetic therapies of hematological malignancies

Pharmacological Research

Volumn 62, Issue 1, 2010, Pages 18-34

  Mercurio, Ciro ^a,b   Minucci, Saverio ^b,c   Pelicci, Pier Giuseppe ^b,c  

^a DAC Genextra Group   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute myeloid leukemia; Chromatin; Epigenetic therapy; HDACi; Leukemia; Lymphoma

Indexed keywords

AMG 655; ANTHRACYCLINE DERIVATIVE; BELINOSTAT; BORTEZOMIB; CHR 2845; DEPSIPEPTIDE; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; ITF 2375; JNJ 26481585; MOCETINOSTAT; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PCI 24781; ROMIDEPSIN; SNDX 275; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER RELAPSE; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; EPIGENETICS; FATIGUE; GENE REPRESSION; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PHARMACODYNAMICS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RECOMMENDED DRUG DOSE; REVIEW; SUMOYLATION; T CELL LEUKEMIA; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR STRUCTURE; TREATMENT OUTCOME;

EID: 77952853306     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.02.010     Document Type: Review

References (216)

1. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8(April(4)):286-298.
2. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293(August(5532)):1074-1080.
3. Wang G.G., Allis C.D., Chi P. Chromatin remodeling and cancer. Part I. Covalent histone modifications. Trends Mol Med 2007, 13(September(9)):363-372.
4. Reid G., Gallais R. Marking time: the dynamic role of chromatin and covalent modification in transcription. Int J Biochem Cell Biol 2009, 41(January(1)):155-163.
5. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 2008;9(March(3)):206-18.
6. Wang Z., Zang C., Cui K., Schones D.E., Barski A., Peng W., et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138(September(5)):1019-1031.
7. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15(June(12)):3958-3969.
8. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F., et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003, (983):84-100.
9. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460(July(7255)):587-591.
10. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007, 404(May(1)):1-13.
11. Mai A. The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets 2007, 11(June(6)):835-851.
12. Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004, 338(April(1)):17-31.
13. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: versatile regulators. Trends Genet 2003, 19(May(5)):286-293.
14. Boyault C., Sadoul K., Pabion M., Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007, 26(August(37)):5468-5476.
15. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(May(6887)):455-458.
16. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002, 277(July(28)):25748-25755.
17. Denslow S.A., Wade P.A. The human Mi-2/NuRD complex and gene regulation. Oncogene 2007, 26(August(37)):5433-5438.
18. You A., Tong J.K., Grozinger C.M., Schreiber S.L. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc Natl Acad Sci USA 2001, 98(February(4)):1454-1458.
19. Wen Y.D., Perissi V., Staszewski L.M., Yang W.M., Krones A., Glass C.K., et al. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc Natl Acad Sci USA 2000, 97(June(13)):7202-7207.
20. Zhang J., Kalkum M., Chait B.T., Roeder R.G. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell 2002, 9(March(3)):611-623.
21. Karagianni P., Wong J. HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 2007, 26(August(37)):5439-5449.
22. Seigneurin-Berny D., Verdel A., Curtet S., Lemercier C., Garin J., Rousseaux S., et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 2001, 21(December(23)):8035-8044.
23. Fischle W., Dequiedt F., Hendzel M.J., Guenther M.G., Lazar M.A., Voelter W., et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002, 9(January(1)):45-57.
24. Fischle W., Dequiedt F., Fillion M., Hendzel M.J., Voelter W., Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001, 276(September(38)):35826-35835.
25. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002, 21(June(11)):2672-2681.
26. Montgomery R.L., Davis C.A., Potthoff M.J., Haberland M., Fielitz J., Qi X., et al. Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev 2007, 21(July(14)):1790-1802.
27. Zimmermann S., Kiefer F., Prudenziati M., Spiller C., Hansen J., Floss T., et al. Reduced body size and decreased intestinal tumor rates in HDAC2-mutant mice. Cancer Res 2007, 67(October(19)):9047-9054.
28. Montgomery R.L., Hsieh J., Barbosa A.C., Richardson J.A., Olson E.N. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc Natl Acad Sci USA 2009, 106(May(19)):7876-7881.
29. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008, 28(March(5)):1688-1701.
30. Vega R.B., Matsuda K., Oh J., Barbosa A.C., Yang X., Meadows E., et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119(Novmber(4)):555-566.
31. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 2004, 24(October(19)):8467-8476.
32. Chang S., Young B.D., Li S., Qi X., Richardson J.A., Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126(July(2)):321-334.
33. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003, 983(March):84-100.
34. Ellis L., Atadja P.W., Johnstone R.W. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009, 8(June(6)):1409-1420.
35. Hadnagy A., Beaulieu R., Balicki D. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Mol Cancer Ther 2008, 7(April(4)):740-748.
36. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(September(9)):769-784.
37. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6(January(1)):38-51.
38. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, December(363):15-23.
39. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275(July(27)):20436-20443.
40. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408(Novmber(6810)):377-381.
41. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005, 18(May(5)):601-607.
42. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280(July(29)):26729-26734.
43. Kekatpure V.D., Dannenberg A.J., Subbaramaiah K. HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009, 284(March(12)):7436-7445.
44. Martínez-Balbás M.A., Bauer U.M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000, 19(February(4)):662-671.
45. Marzio G., Wagener C., Gutierrez M.I., Cartwright P., Helin K., Giacca M. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 2000, 275(April(15)):10887-10892.
46. Nguyen D.X., Baglia L.A., Huang S.M., Baker C.M., McCance D.J. Acetylation regulates the differentiation-specific functions of the retinoblastoma protein. EMBO J 2004, 23(April(7)):1609-1618.
47. Bereshchenko O.R., Gu W., Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002, 32(December(4)):606-613.
48. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325(August(5942)):834-840.
49. Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006, 23(August(4)):607-618.
50. Gargiulo G., Minucci S. Epigenomic profiling of cancer cells. Int J Biochem Cell Biol 2009, 41(January(1)):127-135.
51. Redner R.L., Wang J., Liu J.M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 1999, 94(July(2)):417-428.
52. Jones L.K., Saha V. Chromatin modification, leukaemia and implications for therapy. Br J Haematol 2002, 118(September(3)):714-727.
53. Minucci S., Nervi C., Lo Coco F., Pelicci P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 2001, 20(May(24)):3110-3115.
54. Warrell R.P., Frankel S.R., Miller W.H., Scheinberg D.A., Itri L.M., Hittelman W.N., et al. Differentiation therapy of acute promyelocytic leukemia with all-trans-retinoic acid. N Engl J Med 1991, 324(May(20)):1385-1393.
55. Lin R.J., Evans R.M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 2000, 5(May(5)):821-830.
56. Minucci S., Maccarana M., Cioce M., De Luca P., Gelmetti V., Segalla S., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000, 5(May(5)):811-820.
57. Minucci S., Pelicci P.G. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin Cell Dev Biol 1999, 10(April(2)):215-225.
58. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295(February(5557)):1079-1082.
59. Carbone R., Botrugno O.A., Ronzoni S., Insinga A., Di Croce L., Pelicci P.G., et al. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 2006, 26(February(4)):1288-1296.
60. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell R.P., Rifkind R.A., et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001, 108(Novmber(9)):1321-1330.
61. Peterson L.F., Zhang D.E. The 8;21 translocation in leukemogenesis. Oncogene 2004, 23(May(24)):4255-4262.
62. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998, 95(September(18)):10860-10865.
63. Lutterbach B., Westendorf J.J., Linggi B., Patten A., Moniwa M., Davie J.R., et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998, 18(December(12)):7176-7184.
64. Gelmetti V., Zhang J., Fanelli M., Minucci S., Pelicci P.G., Lazar M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998, 18(December(12)):7185-7191.
65. Wang J., Wang M., Liu J.M. Domains involved in ETO and human N-CoR interaction and ETO transcription repression. Leuk Res 2004, 28(April(4)):409-414.
66. Zhang J., Hug B.A., Huang E.Y., Chen C.W., Gelmetti V., Maccarana M., et al. Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol 2001, 21(January(1)):156-163.
67. Barbetti V., Gozzini A., Rovida E., Morandi A., Spinelli E., Fossati G., et al. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Oncogene 2008, 27(March(12)):1767-1778.
68. Liu S., Klisovic R.B., Vukosavljevic T., Yu J., Paschka P., Huynh L., et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 2007, 321(June(3)):953-960.
69. Wang J., Saunthararajah Y., Redner R.L., Liu J.M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999, 59(June(12)):2766-2769.
70. Nebbioso A., Clarke N., Voltz E., Germain E., Ambrosino C., Bontempo P., et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005, 11(January(1)):77-84.
71. Durst K.L., Lutterbach B., Kummalue T., Friedman A.D., Hiebert S.W. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 2003, 23(January(2)):607-619.
72. Shigesada K., van de Sluis B., Liu P.P. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene 2004, 23(May(24)):4297-4307.
73. Serrano E., Carnicer M.J., Lasa A., Orantes V., Pena J., Brunet S., et al. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. Leuk Res 2008, 32(June(6)):944-953.
74. Ferrando A.A., Herblot S., Palomero T., Hansen M., Hoang T., Fox E.A., et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood 2004, 103(March(5)):1909-1911.
75. O'Neil J., Shank J., Cusson N., Murre C., Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 2004, 5(June(6)):587-596.
76. Shaffer A.L., Rosenwald A., Staudt L.M. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002, 2(December(12)):920-932.
77. Dhordain P., Lin R.J., Quief S., Lantoine D., Kerckaert J.P., Evans R.M., et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 1998, 26(October(20)):4645-4651.
78. Lemercier C., Brocard M.P., Puvion-Dutilleul F., Kao H.Y., Albagli O., Khochbin S. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J Biol Chem 2002, 277(June(24)):22045-22052.
79. O'Connor O.A. Targeting histones and proteasomes: new strategies for the treatment of lymphoma. J Clin Oncol 2005, 23(September(26)):6429-6436.
80. Bradbury C.A., Khanim F.L., Hayden R., Bunce C.M., White D.A., Drayson M.T., et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005, 19(October(10)):1751-1759.
81. Wada T., Kikuchi J., Nishimura N., Shimizu R., Kitamura T., Furukawa Y. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem 2009, 284(October(44)):30673-30683.
82. Garcia-Manero G, Quesada AS, Maddipoti S, Kuang S, Tong W, Wierda WG. Analysis of class I and II histone deacetylase fails to identify a human leukemia specific expression profile. Blood (ASH annual meeting abstracts) 2007;110 [Abstract 2130].
83. Marquard L., Poulsen C.B., Gjerdrum L.M., de Nully Brown P., Christensen I.J., Jensen P.B. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54(May(6)):688-698.
84. Marquard L., Gjerdrum L.M., Christensen I.J., Jensen P.B., Sehested M., Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008, 53(September(3)):267-277.
85. Wang J.C., Chen C., Dumlao T., Naik S., Chang T., Xiao Y.Y., et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008, 49(December(12)):2321-2327.
86. Lee S.M., Bae J.H., Kim M.J., Lee H.S., Lee M.K., Chung B.S., et al. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther 2007, 322(September(3)):1084-1092.
87. Nimmanapalli R., Fuino L., Stobaugh C., Richon V., Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101(April(8)):3236-3239.
88. Fiskus W., Pranpat M., Balasis M., Bali P., Estrella V., Kumaraswamy S., et al. Cotreatment with Vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006, 12(October(19)):5869-5878.
89. Okabe S., Tauchi T., Nakajima A., Sashida G., Gotoh A., Broxmeyer H.E., et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007, 16(June(3)):503-514.
90. Kircher B., Schumacher P., Petzer A., Hoflehner E., Haun M., Wolf A.M., et al. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol 2009, 83(July(1)):48-56.
91. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105(February(4)):1768-1776.
92. Insinga A., Monestiroli S., Ronzoni S., Gelmetti V., Marchesi F., Viale A., et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005, 11(January(1)):71-76.
93. Krämer O.H., Müller S., Buchwald M., Reichardt S., Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. FASEB J 2008, 22(May(5)):1369-1379.
94. Zardo G., Cimino G., Nervi C. Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. Leukemia 2008, 22(August(8)):1503-1518.
95. Laribee R.N., Klemsz M.J. Loss of PU.1 expression following inhibition of histone deacetylases. J Immunol 2001, 167(Novmber(9)):5160-5166.
96. Milhem M., Mahmud N., Lavelle D., Araki H., DeSimone J., Saunthararajah Y., et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood 2004, 103(June(11)):4102-4110.
97. De Felice L., Tatarelli C., Mascolo M.G., Gregorj C., Agostini F., Fiorini R., et al. Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res 2005, 65(February(4)):1505-1513.
98. Bug G., Gül H., Schwarz K., Pfeifer H., Kampfmann M., Zheng X., et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65(April(7)):2537-2541.
99. Gül H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A, Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 2009(June) [Epub ahead of print].
100. Gül H., Marquez-Curtis L.A., Jahroudi N., Lo J., Turner A.R., Janowska-Wieczorek A., et al. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev 2009, 18(July-August(6)):831-838.
101. Fiskus W., Pranpat M., Balasis M., Herger B., Rao R., Chinnaiyan A., et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006, 5(December(12)):3096-3104.
102. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor Panobinostat against human AML cells. Blood 2009, 114(September(13)):2733-2743.
103. Marson C.M. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem 2009, 9(July(6)):661-692.
104. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27(Novmber(32)):5459-5468.
105. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107(July(4)):600-608.
106. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA 2003, 100(April(8)):4389-4394.
107. Ontoria J.M., Altamura S., Di Marco A., Ferrigno F., Laufer R., Muraglia E., et al. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy. J Med Chem 2009, 52(Novmber(21)):6782-6789.
108. Mai A., Massa S., Pezzi R., Simeoni S., Rotili D., Nebbioso A., et al. Class II (IIA)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem 2005, 48(May(9)):3344-3353.
109. Buchwald M., Krämer O.H., Heinzel T. HDACi-targets beyond chromatin. Cancer Lett 2009, 280(August(2)):160-167.
110. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005, 14(December(12)):1497-1511.
111. Ungerstedt J.S., Sowa Y., Xu W.S., Shao Y., Dokmanovic M., Perez G., et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005, 102(January(3)):673-678.
112. Marks P.A., Richon V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92(August(15)):1210-1216.
113. Gabrielli B.G., Johnstone R.W., Saunders N.A. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr Cancer Drug Targets 2002, 2(December(4)):337-353.
114. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000, 97(August(18)):10014-10019.
115. Hitomi T., Matsuzaki Y., Yokota T., Takaoka Y., Sakai T. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 2003, 554(Novmber(3)):347-350.
116. Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003, 2(February(2)):151-163.
117. Qiu L., Burgess A., Fairlie D.P., Leonard H., Parsons P.G., Gabrielli B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000, 11(June(6)):2069-2083.
118. Schrump D.S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009, 15(June(12)):3947-3957.
119. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(August(37)):5541-5552.
120. Sutheesophon K., Nishimura N., Kobayashi Y., Furukawa Y., Kawano M., Itoh K., et al. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor Depsipeptide (FK228). J Cell Physiol 2005, 203(May(2)):387-397.
121. Zhang X.D., Gillespie S.K., Borrow J.M., Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004, 3(April(4)):425-435.
122. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001, 98(September(19)):10833-10838.
123. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003, 2(December(12)):1273-1284.
124. Shao Y., Gao Z., Marks P.A., Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004, 101(December(52)):18030-18035.
125. Xu W.S., Perez G., Ngo L., Gui C.Y., Marks P.A. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 2005, 65(September(17)):7832-7839.
126. Cimini D., Mattiuzzo M., Torosantucci L., Degrassi F. Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol Biol Cell 2003, 14(September(9)):3821-3833.
127. Taddei A., Roche D., Bickmore W.A., Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?. EMBO Rep 2005, 6(June(6)):520-524.
128. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008, 8(March(2)):132-140.
129. Epping M.T., Wang L., Plumb J.A., Lieb M., Gronemeyer H., Brown R., et al. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 2007, 104(Novmber(45)):17777-17782.
130. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009, 15(January(1)):57-66.
131. Ellis L., Hammers H., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009, 280(August(2)):145-153.
132. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 2004, 315(March(4)):964-970.
133. Maeda T., Towatari M., Kosugi H., Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000, 96(December(12)):3847-3856.
134. Reddy P., Maeda Y., Hotary K., Liu C., Reznikov L.L., Dinarello C.A., et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004, 101(March(11)):3921-3926.
135. Fantin V.R., Richon V.M. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007, 13(December(24)):7237-7242.
136. Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007, 104(May(19)):8071-8076.
137. Newbold A., Lindemann R.K., Cluse L.A., Whitecross K.F., Dear A.E., Johnstone R.W. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor Romidepsin. Mol Cancer Ther 2008, 7(May(5)):1066-1079.
138. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A. Constitutive activation of signal transducers and activators of transcription predicts Vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008, 68(May(10)):3785-3794.
139. Xu W., Ngo L., Perez G., Dokmanovic M., Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 2006, 103(October(42)):15540-15545.
140. Saunders L.R., Verdin E. Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors. Mol Cancer Ther 2006, 5(Novmber(11)):2777-2785.
141. Xiao JJ, Huang Y, Dai Z, Sadée W, Chen J, Liu S, et al. Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 2005;314(July(1)):467-75.
142. Hauswald S., Duque-Afonso J., Wagner M.M., Schertl F.M., Lübbert M., Peschel C., et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res 2009, 15(June(11)):3705-3715.
143. Kelly W.K., Marks P.A. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2(March(3)):150-157.
144. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26(February(9)):1351-1356.
145. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24(January(1)):166-173.
146. Crump M., Coiffier B., Jacobsen E.D., Sun L., Ricker J.L., Xie H., et al. Phase II trial of oral Vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19(May(5)):964-969.
147. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12(October(10)):1247-1252.
148. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16(July(7)):1111-20; 12(October(10)):1247-52.
149. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., et al. Phase IIB multicenter trial of Vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25(July(21)):3109-3115.
150. Mann B.S., Johnson J.R., He K., Sridhara R., Abraham S., Booth B.P., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 2007, 13(April(8)):2318-2322.
151. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral Vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109(January(1)):31-39.
152. Fantin V.R., Loboda A., Paweletz C.P., Hendrickson R.C., Pierce J.W., Roth J.A., et al. Constitutive activation of signal transducers and activators of transcription predicts Vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 2008, 68(May(10)):3785-3794.
153. Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood (ASH annual meeting abstracts) 2007;110:2574.
154. Kirschbaum MH, Zain JM, Popplewell L, Pullarkat V, Nademanee AP, Delioukina ML, et al. A phase 2 study of Vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non Hodgkin lymphoma. A California Cancer Consortium Study. Blood (ASH annual meeting abstracts) 2007;110:2568.
155. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor Vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111(February(3)):1060-1066.
156. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., et al. Phase I trial of oral Vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49(March(3)):502-507.
157. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409(January(2)):581-589.
158. Gimsing P. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs 2009, 18(April(4)):501-508.
159. Gimsing P., Hansen M., Knudsen L.M., Knoblauch P., Christensen I.J., Ooi C.E., et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 2008, 81(September(3)):170-176.
160. Zain JM, Foss F, Kelly WK, DeBono J, Petrylak D, Narwal A, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma J Clin Oncol (ASCO annual meeting 2009) 2009;27:15s(Suppl) [Abstract 8580].
161. Pohlman B, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, et al. Final results of a phase II trial of Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH annual meeting abstract) 2009:920 [Abstract].
162. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 2009, 5(June(5)):601-612.
163. Atadja P. Development of the pan-DAC inhibitor Panobinostat (LBH589): successes and challenges. Cancer Lett 2009, 280(August(2)):233-241.
164. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006, 12(August(15)):4628-4635.
165. Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J Clin Oncol 2007;25:18S(June(Suppl)) [14019].
166. Prince HM, George DJ, Patnaik A, Mita N, Dugan M, Butterfoss D, et al. Phase study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and Non-Hodgkin's lymphoma J Clin Oncol 2007;25 [Abstract 3500].
167. Ellis L., Pan Y., Smyth G.K., George D.J., McCormack C., Williams-Truax R., et al. Histone deacetylase inhibitor Panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008, 14(July(14)):4500-4510.
168. Duvic FV, Vanaclocha F, Bernengo MG, Okada C, Breneman D, Zinzani PL, et al. Phase II trial of oral Panobinostat (LBH589) in patients with refractory cutaneous T-cell. J Clin Oncol 2008;26(May(Suppl)) [Abstract 8555 1005].
169. Dickinson M., Ritchie D., DeAngelo D.J., Spencer A., Ottmann O.G., Fischer T., et al. Preliminary evidence of disease response to the pan deacetylase inhibitor Panobinostat (LBH589) in refractory Hodgkin lymphoma. Br J Haematol 2009, 147(October(1)):97-101.
170. Younes A, Ong T-C, Ribrag V, Engert A, Ben-Yehuda D, McCabe R. Efficacy of Panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. Blood (ASH annual meeting) 2009;(December) [Abstract: 923].
171. Ottmann OG, Spencer A, Miles Prince H, Bhalla KN, Fischer T, Liu A, et al., Phase IA/II study of oral Panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 958].
172. Wolf JL, Siegel D, Matous J, Lonial S, Goldschmidt H, Schmitt S, et al., A phase II study of oral Panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 4254].
173. Zaritskey A, Alimena G, Konopka L, Shamsazar J, Bourquelot PM, Jallaludain M, et al. A phase II study of oral Panobinostat (LBH589) for chronic phase chronic myeloid leukemia (CML) with resistance to ≥2 BCR-ABL tyrosine kinase inhibitors. Blood (ASH annual meeting abstracts) 2008;112(November):4254.
174. Leoni F., Fossati G., Lewis E.C., Lee J.K., Porro G., Pagani P., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005, 11(January-December(1-12)):1-15.
175. Galli M., Salmoiraghi S., Golay J., Gozzini A., Crippa C., Pescosta N., et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010, 89(February(2)):185-190.
176. Viviani S, Bonfante V, Fasola C, Valagussa P, Gianni AM. Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients. J Clin Oncol 2008;26(May(Suppl)) [Abstract 8532].
177. Rambaldi A, Dellacasa CM, Salmoiraghi S, Spinelli O, Ferrari ML, Gattoni E, et al. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 100].
178. Bonfils C., Kalita A., Dubay M., Siu L.L., Carducci M.A., Reid G., et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008, 14(June(11)):3441-3449.
179. Kell J. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer. Curr Opin Investig Drugs 2007, 8(June(6)):485-492.
180. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008, 7(April(4)):759-768.
181. Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitorbased therapies and haematological malignancy. Ann Oncol 2009;20(August(8)):1293-302.
182. Garcia-Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112(August(4)):981-9.
183. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-7.
184. Crump M, Andreadis C, Assouline S, Rizzieri D, Wedgwood A, McLaughlin P, et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. J Clin Oncol 2008;26(May(Suppl)) [Abstract 8528].
185. Bociek RG, Kuruvilla J, Pro B, Wedgwood A, Li Z, Drouin M, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL). J Clin Oncol 2008;26(May(Suppl)) [Abstract 8507].
186. Hess-Stumpp H., Bracker T.U., Henderson D., Politz O. MS-275, a potent orally available inhibitor of histone deacetylases-the development of an anticancer agent. Int J Biochem Cell Biol 2007, 39(7-8):1388-1405.
187. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23(June(17)):3912-3922.
188. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109(April(7)):2781-2790.
189. Kummar S., Gutierrez M., Gardner E.R., Donovan E., Hwang K., Chung E.J., et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 2007, 13(September(18 Pt 1)):5411-5417.
190. Altucci L., Minucci S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur J Cancer 2009, 45(May(7)):1137-1145.
191. Konstantinopoulos P.A., Vandoros G.P., Papavassiliou A.G. FK228 (Depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities. Cancer Chemother Pharmacol 2006, 58(Novmber(5)):711-715.
192. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., et al. A phase 1 and pharmacodynamic study of Depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105(February(3)):959-967.
193. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of Depsipeptide (Romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008, 14(February(3)):826-832.
194. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm189629.htm.
195. Kim Y, Whittaker S, Demierre MF, Rook AH, Lerner A, Duvic M, et al. Clinically significant responses achieved with Romidepsin in treatment-refractory cutaneous T-cell lymphoma: final results from a phase 2B, International, Multicenter, Registration Study. Blood (ASH annual meeting abstracts) 2008;112 [Abstract 263].
196. Bates S, Piekarz R, Wright J, Frye R, Figg Sr. WD, Allen AL, et al. Final clinical results of a phase 2 NCI multicenter study of Romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). Blood (ASH annual meeting abstracts) 2008;112 [Abstract 1568].
197. Bates S.E., Zhan Z., Steadman K., Obrzut T., Luchenko V., Frye R., et al. Laboratory correlates for a phase II trial of Romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010, 148(January(2)):256-267.
198. Piekarz R, Wright J, Frye R, Allen SL, Craig M, Geskin L. Results of a phase 2 NCI multicenter study of Romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood (ASH annual meeting abstracts) 2008;112(November):1567.
199. Niesvizky R, Ely S, DiLiberto M, Cho HJ, Gelbshtein UY, Jayabalan DS, et al. Multicenter phase II trial of the histone deacetylase inhibitor Depsipeptide (FK228) for the treatment of relapsed or refractory multiple myeloma (MM). Blood (ASH annual meeting abstracts) 2005;106(November):2574.
200. Odenike O.M., Alkan S., Sher D., Godwin J.E., Huo D., Brandt S.J., et al. Histone deacetylase inhibitor Romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 2008, 14(Novmber(21)):7095-7101.
201. Piekarz R.L., Frye A.R., Wright J.J., Steinberg S.M., Liewehr D.J., Rosing D.R., et al. Cardiac studies in patients treated with Depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12(June(12)):3762-3773.
202. http://www.clinical%20trial%20gov/.
203. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009, 15(June(12)):3970-3977.
204. Rodriguez-Gonzalez A., Lin T., Ikeda A.K., Simms-Waldrip T, Fu C., Sakamoto K.M. Role oft he aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008, 68:2557-2560.
205. Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, Sakamoto KM. The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 2008;94(July(3)):283-6.
206. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108(Novmber(10)):3441-3449.
207. Badros A., Burger A.M., Philip S., Niesvizky R., Kolla S.S., Goloubeva O., et al. Phase I study of Vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009, 15(August(16)):5250-5257.
208. Siegel D, Sezer O, San Miguel JF, Mateos M-V, Prosser I, Cavo M, et al. Phase IB, multicenter, open-label, dose-escalation study of oral Panobinostat (LBH589) and I.V. bortezomib in patients with relapsed multiple myeloma. Blood (ASH annual meeting abstracts) 2008;112(November):2781.
209. Harrison SJ, Quach H, Yuen K, Strayer A, Copeman MC, Phil D, et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor Romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood (ASH annual meeting abstracts) 2008;112(November):3698.
210. Rasheed W.K., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007, 16(May(5)):659-678.
211. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20(January(1)):1-13.
212. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(January(1)):103-7.
213. Silverman LR, Verma A, Odchimar-Reissig R, Cozza A, Najfeld V, Litch JD, et al. Phase I/II study of Vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome(MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium [abstract]. J Clin Oncol (meeting abstracts) 2008;26(Suppl 15):7000.
214. Odenike O, Green M, Larson RA, Rich ES, Ott J, Ratain MJ, et al. Phase I study of belinostat (PXD101) plus azacitidine(AZC) in patients with advanced myeloid neoplasms. J Clin Oncol (meeting abstracts) 2008;26(Suppl 15):7057.
215. Garcia-Manero G, Tambaro FP, Bekele BN, Jabbour E, Ravandi F, Yang H, et al. Phase II study of Vorinostat in combination with Idarubicin (Ida) and Cytarabine (ara-C) as front line therapy in acute myelogenous leukemia (AML) or higher risk myelodysplastic syndrome (MDS). Blood (ASH annual meeting abstracts) 2008;112(November):1055.
216. Welsbie D.S., Xu J., Chen Y., Borsu L., Scher H.I., Rosen N., et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009, 69(February(3)):958-966.